MX2023006474A - Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico. - Google Patents
Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico.Info
- Publication number
- MX2023006474A MX2023006474A MX2023006474A MX2023006474A MX2023006474A MX 2023006474 A MX2023006474 A MX 2023006474A MX 2023006474 A MX2023006474 A MX 2023006474A MX 2023006474 A MX2023006474 A MX 2023006474A MX 2023006474 A MX2023006474 A MX 2023006474A
- Authority
- MX
- Mexico
- Prior art keywords
- lupus erythematosus
- methods
- treating cutaneous
- systemic lupus
- systemic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121194P | 2020-12-03 | 2020-12-03 | |
| PCT/US2021/061764 WO2022120144A1 (en) | 2020-12-03 | 2021-12-03 | Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006474A true MX2023006474A (es) | 2023-08-16 |
Family
ID=79024222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006474A MX2023006474A (es) | 2020-12-03 | 2021-12-03 | Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240018246A1 (https=) |
| EP (1) | EP4255392A1 (https=) |
| JP (1) | JP2024501430A (https=) |
| KR (1) | KR20230119664A (https=) |
| CN (1) | CN116963716A (https=) |
| AR (1) | AR124247A1 (https=) |
| AU (1) | AU2021391803A1 (https=) |
| CA (1) | CA3203971A1 (https=) |
| CL (1) | CL2023001562A1 (https=) |
| CO (1) | CO2023008272A2 (https=) |
| IL (1) | IL303279A (https=) |
| MX (1) | MX2023006474A (https=) |
| PE (1) | PE20231678A1 (https=) |
| TW (1) | TW202222829A (https=) |
| WO (1) | WO2022120144A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU785198B2 (en) * | 1999-11-15 | 2006-11-02 | Miltenyi Biotec B.V. & Co. KG | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby |
| CN111961134B (zh) * | 2012-12-10 | 2024-04-05 | 比奥根Ma公司 | 抗血液树突细胞抗原2抗体及其用途 |
| US10294301B2 (en) * | 2013-12-24 | 2019-05-21 | Astellas Pharma Inc. | Anti-human BDCA-2 antibody |
| MA44763A (fr) | 2016-04-28 | 2019-03-06 | Biogen Ma Inc | Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang |
-
2021
- 2021-12-03 CA CA3203971A patent/CA3203971A1/en active Pending
- 2021-12-03 AU AU2021391803A patent/AU2021391803A1/en active Pending
- 2021-12-03 AR ARP210103370A patent/AR124247A1/es unknown
- 2021-12-03 EP EP21827347.2A patent/EP4255392A1/en active Pending
- 2021-12-03 MX MX2023006474A patent/MX2023006474A/es unknown
- 2021-12-03 TW TW110145254A patent/TW202222829A/zh unknown
- 2021-12-03 IL IL303279A patent/IL303279A/en unknown
- 2021-12-03 KR KR1020237022397A patent/KR20230119664A/ko active Pending
- 2021-12-03 WO PCT/US2021/061764 patent/WO2022120144A1/en not_active Ceased
- 2021-12-03 US US18/038,911 patent/US20240018246A1/en active Pending
- 2021-12-03 JP JP2023533928A patent/JP2024501430A/ja active Pending
- 2021-12-03 PE PE2023001760A patent/PE20231678A1/es unknown
- 2021-12-03 CN CN202180091232.0A patent/CN116963716A/zh active Pending
-
2023
- 2023-05-31 CL CL2023001562A patent/CL2023001562A1/es unknown
- 2023-06-23 CO CONC2023/0008272A patent/CO2023008272A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240018246A1 (en) | 2024-01-18 |
| KR20230119664A (ko) | 2023-08-16 |
| IL303279A (en) | 2023-07-01 |
| JP2024501430A (ja) | 2024-01-12 |
| CA3203971A1 (en) | 2022-06-09 |
| AR124247A1 (es) | 2023-03-01 |
| TW202222829A (zh) | 2022-06-16 |
| AU2021391803A1 (en) | 2023-07-06 |
| CL2023001562A1 (es) | 2023-12-15 |
| EP4255392A1 (en) | 2023-10-11 |
| AU2021391803A9 (en) | 2024-09-26 |
| PE20231678A1 (es) | 2023-10-19 |
| WO2022120144A1 (en) | 2022-06-09 |
| CO2023008272A2 (es) | 2023-09-29 |
| CN116963716A (zh) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551865A1 (en) | Anti-msr1 antibodies and methods of use thereof | |
| MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
| MX2024013523A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t | |
| MX2025005315A (es) | Celulas t para usarse en el tratamiento de una enfermedad o afeccion | |
| MX2025002021A (es) | Inmunoterapia con receptores de antigeno quimerico y uso de la misma | |
| WO2020113194A3 (en) | Methods for treatment using adoptive cell therapy | |
| EP4219690A3 (en) | Methods of cancer treatment using activated t cells | |
| MX2022012991A (es) | Anticuerpos anti-vista humanos y uso de estos. | |
| CY1114445T1 (el) | Ενωσεις 2,4-πυριμιδινοδιαμινης για χρηση στη θεραπευτικη αγωγη ή προληψη αυτοανοσων ασθενειων | |
| ATE540709T1 (de) | Implantierbare medizinische vorrichtung mit partikelbeschichtung | |
| MX2021005646A (es) | Métodos de tratamiento de cáncer con agentes de unión a tubulina. | |
| PH12013500826A1 (en) | Means and methods for treating dlbcl | |
| WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| WO2022026360A3 (en) | Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use | |
| TW200637574A (en) | Treatment method | |
| IL178042A0 (en) | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation | |
| MX2021013394A (es) | Métodos para administrar inmunoterapia con receptor de antígeno quimérico. | |
| MX2020008718A (es) | Anticuerpos de union a bcma y usos de los mismos. | |
| MX2023006474A (es) | Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico. | |
| WO2022197930A3 (en) | Panels and methods for treatment of diffuse large b-cell lymphoma | |
| WO2021056025A3 (en) | Anti-epha10 antibodies and methods of use thereof | |
| WO2006002377A3 (en) | Optimized dosing with anti-cd4 antibodies for tolerance induction in primates | |
| JOP20210279A1 (ar) | طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي | |
| MX2021006573A (es) | Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20. | |
| ATE254451T1 (de) | Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten |